Gastrointestinal Stromal Tumor New Drug
In a nutshell, here are the several basic points about GIST treatment.
● Surgery in order to remove Gastrointestinal Stromal Tumor is the first step when possible.
● It is potentially curative treatment for primary Gastrointestinal Stromal tumors that have yet to metastasize, but the probability of the recurrence depends on the characteristics of the tumor.
● Initially tumors that are inoperable can be pre-treated with the imatinib in order to improve resectability.
● After the complete removal of a primary GIST, patients with a higher risk of tumor recurrence can consider adjuvant treatment with the imatinib mesylate 400 mg.
● Patients who are with the metastatic GIST disease, even if removed, required a drug treatment in order to maintain the controlling of disease.
● GIST patients whose tumors become resistant to imatinib, sunitinib is a second-line drug treatment.
● FDA-approved regorafenib drug as a third-line treatment for those patients whose tumors are not responding to the sunitinib or imatinib.
● Several other drugs approved for other conditions can be prescribed off-label for Gastrointestinal Stromal Tumor.
Early Stages of Gastrointestinal Stromal Tumor: Staging is a way in order to describe a cancer in terms of the size, location, and whether it has spread to other organs or tissues.
Very Low Risk:
● Smaller than the 2 cm, less than 5/50 High Powered Field
Low Risk:
● 2-5 cm, less than the 5/50 High Powered Field
Intermediate Risk
● Larger than the 5 cm, 6-10/50 High Powered Field
● 5-10 cm, less than the 5/50 High Powered Field
High Risk:
● More than the 5 cm, more than 5/50 High Powered Field
● More than the 10 cm, any mitotic rate
● Any size, more than the 10/50 High Powered Field
Gastrointestinal stromal tumor symptoms: Small GISTs are often found when the patient has a routine test or procedure for some other problem. There may be no warning symptoms. Larger tumors can be responsible for causing pain, vomiting, loss of appetite, nausea, weight loss, early feelings of fullness, fatigue, bleeding and bloating.
How Does Gastrointestinal Stromal Tumor Spread?
Gastrointestinal Stromal Tumor usually begins when a kit gene in the center (nucleus) of a cell has a defect (mutation).
The kit gene is involved in making a protein, known as KIT. This protein (KIT) is found on the surface of the cell. This protein is part of the system that is involved in making a cell divide as well as grow. Mutation of kit genes, the KIT protein often becomes too active. It indicates the cell in order to grow as well as divide without interrupting and with no turn off. The cells divide abnormally and form a tumor.
Mutations in kit are found in 90 to 95% of GISTs. GIST can grow gradually and remain stable for several years. Or, it can progress rapidly, metastasizing to other parts of the body. GIST most often occurs in adults between the ages of 40 and 80 years. The average age at first diagnosis is 63 years. It occurs a bit more often in male than females. Risk factors are unknown but you are more likely at small increased risk if someone in your family has had this disease.
Gastrointestinal stromal tumor treatment: Surgery: Surgery is the key treatment for the GIST tumors that have yet to spread. There are less chances that GISTs spread to the lymph nodes. Lymph nodes generally do not need to be removed. Surgery can also be recommended after treatment with the targeted therapy. Therapy helps to shrink the tumor, making the surgery possible.
Radiation: Gastrointestinal Stromal Tumors tend not to respond to radiation treatments. Sometimes, radiation can be used in order to treat signs of a lesion which has spread.
Chemotherapy: Chemotherapy treatment is quite effective on GISTs. Targeted therapies basically known as selective tyrosine kinase inhibitors have been recommended in order to disrupt the abnormally active KIT protein. An oral chemotherapy medication (gleevec 100 mg) is quite popular amongst doctors.
Gleevec uses: Gleevec 400 mg basically a chemotherapy medication recommended for treating chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of GIST (gastrointestinal stromal tumors), systemic mastocytosis, chronic eosinophilic leukemia (CEL), hypereosinophilic syndrome (HES), and myelodysplastic syndrome.
Clinical Trials: Clinical trials can be offered at the Cancer Center. Ask your healthcare provider how you can be a part of these trials. They can help in order to find advance and better treatment options for people who are with the GIST.
Prescribing Information: For full information please see "PI". Before initiating any treatment consult a doctor.
Prescribing Information: For full information please see "PI". Before initiating any treatment consult a doctor.
Tollfree - +91 1800 889 1064
International Pharmaceutical Wholesalers
